Comparative study of the soluble forms of immune checkpoint proteins VISTA, PD-1, PD-l1, and bone homeostasis regulator RANKL in bone tumor patients
- 作者: Gershtein E.S.1,2, Kuzmin Y.B.1,2, Alferov A.A.1,2, Korotkova E.A.1, Tsarapaev P.V.1, Sokolov N.Y.3, Kuznetsov I.N.2, Vashketova O.I.1, Kozlova E.V.1, Yanushevich O.O.2, Boulytcheva I.V.1, Stilidi I.S.1, Kushlinskii N.E.1,2
-
隶属关系:
- N.N. Blokhin National Medical Research Center of Oncology
- A.I. Evdokimov Moscow State University of Medicine and Dentistry
- S.P. Botkin Сity Clinical Hospital
- 期: 卷 20, 编号 6 (2022)
- 页面: 25-32
- 栏目: Original research
- URL: https://journals.eco-vector.com/1728-2918/article/view/321294
- DOI: https://doi.org/10.29296/24999490-2022-06-04
- ID: 321294
如何引用文章
详细
Background. Low sensitivity of bone tumors to various schemes of standard chemotherapy stimulated the search of new targets for their medicamentous treatment. Among such targets are the so-called “immune checkpoints” promoting the escape of the tumor from the immune response of the organism, and some proteins directly affecting the remodeling and homeostasis of bone tissue.
The aim of this study was the comparative evaluation of the content of the soluble forms of VISTA, PD-1, PD-L1, and RANKL in blood serum of patients with malignant and borderline bone tumors, and practically healthy persons; analysis of the associations between these markers and the key clinical and pathological features of bone tumors.
Material and methods. The study enclosed 82 patients with malignant bone tumors (osteosarcoma – 50, chondrosarcoma – 16, chordoma – 12, Ewing sarcoma – 4), 18 patients with borderline giant-cell bone tumor (GCBT), and 29 practically healthy persons. Proteins’ content was measured in blood serum with standard ELISA kits: «Human VISTA/B7-H5/PD-1H ELISA Кit» (RayBiotech,), «Human PD-L1 Platinum ELISA», «Human PD-1 ELISA kit» (Affimetrix, eBioscience), «ampli-sRANKL» (Biomedica Medizinprodukte).
Results. In patients with bone sarcomas, a statistically significant increase in the level of sPD-L1 was revealed, as well as a pronounced trend towards a decrease in the levels of sVISTA and an increase in sRANKL compared with the control, while the level of sPD-1 practically did not differ from the control. A weak positive correlation between sVISTA and sPD-1 serum levels most prominent in chordoma patients (rs=0.63) was observed. Significant positive correlation was also found between sPD-1 and sRANKL concentrations. sVISTA and sRANKL levels did not differ significantly between histological types of bone sarcomas. More than 20-fold increase of sVISTA level in Ewing sarcoma patients as compared to other malignant bone neoplasms did not reach the statistical significance level. The highest sPD-1 level was also observed in Ewing sarcoma, the difference with chordoma and chondrosarcoma being statistically significant. In GCBT patients both sPD-L1 and sPD-1 levels were significantly increased as compared to control, sVISTA level did not differ from control, while sRANKL was significantly higher than both in control, and in bone sarcoma patients. Negative correlation between sVISTA and sRANKL (rs=-0.67) was also observed in this patients group.
Conclusion. Multidirectional changes in the levels of soluble forms of the proteins affected by targeted immunotherapy in peripheral blood of malignant and borderline bone tumor patients were demonstrated. The most prominent changes were found in the neoplasms with specific origin – GCBT and Ewing sarcoma that has a neuroectodermal derivation. Presumably, these diseases are the most plausible candidates for immune modulatory therapies.
关键词
全文:

作者简介
Elena Gershtein
N.N. Blokhin National Medical Research Center of Oncology; A.I. Evdokimov Moscow State University of Medicine and Dentistry
编辑信件的主要联系方式.
Email: esgershtein@gmail.com
ORCID iD: 0000-0002-3321-801X
Doctor of Biological Sciences, Professor, leading researcher, Laboratory of Clinical Biochemistry
俄罗斯联邦, Kashirskoe shosse, 23, Moscow, 115522; St. Delegatskaya, 20/2, Moscow, 127473Yury Kuzmin
N.N. Blokhin National Medical Research Center of Oncology; A.I. Evdokimov Moscow State University of Medicine and Dentistry
Email: yriikuzmin@yandex.com
ORCID iD: 0000-0001-9684-2509
Laboratory assistant-researcher, Laboratory of Clinical Biochemistry
俄罗斯联邦, Kashirskoe shosse, 23, Moscow, 115522; St. Delegatskaya, 20/2, Moscow, 127473Aleksandr Alferov
N.N. Blokhin National Medical Research Center of Oncology; A.I. Evdokimov Moscow State University of Medicine and Dentistry
Email: aleksandr.alferov@yahoo.com
ORCID iD: 0000-0003-3585-5693
Candidate of Medical Sciences, Doctor of Clinical Laboratory Diagnostics, Laboratory of Clinical Biochemistry
俄罗斯联邦, Kashirskoe shosse, 23, Moscow, 115522; St. Delegatskaya, 20/2, Moscow, 127473Ekaterina Korotkova
N.N. Blokhin National Medical Research Center of Oncology
Email: katinka-kor@yandex.ru
ORCID iD: 0000-0002-2509-5232
Candidate of Biological Sciences, Senior Researcher, Laboratory of Clinical Biochemistry
俄罗斯联邦, Kashirskoe shosse, 23, Moscow, 115522Pavel Tsarapaev
N.N. Blokhin National Medical Research Center of Oncology
Email: pcarapaev96@gmail.com
ORCID iD: 0000-0002-1182-1010
Laboratory Assistant-Researcher, Laboratory of Clinical Biochemistry
俄罗斯联邦, Kashirskoe shosse, 23, Moscow, 115522Nikolai Sokolov
S.P. Botkin Сity Clinical Hospital
Email: strivp@mail.ru
ORCID iD: 0000-0002-0706-9575
Candidate of Medical Sciences, Head of the Department of Antitumor Drug Therapy No. 15
俄罗斯联邦, 2nd Botkinsky pr-d, 5, Moscow, 125284Igor Kuznetsov
A.I. Evdokimov Moscow State University of Medicine and Dentistry
Email: biochimia@yandex.ru
Candidate of Medical Sciences, Senior Laboratory Assistant, Department of Clinical Biochemistry and Laboratory Diagnostics
俄罗斯联邦, St. Delegatskaya, 20/2, Moscow, 127473Olga Vashketova
N.N. Blokhin National Medical Research Center of Oncology
Email: biochimia@yandex.ru
ORCID iD: 0000-0003-3387-6634
Candidate of Medical Sciences, Senior Researcher, Laboratory of Clinical Biochemistry
俄罗斯联邦, Kashirskoe shosse, 23, Moscow, 115522Elizaveta Kozlova
N.N. Blokhin National Medical Research Center of Oncology
Email: elizavetaklv@mail.ru
ORCID iD: 0000-0003-2484-020X
Postgraduate Student, Department of Morphological and Molecular Genetic Tumor Diagnostics
俄罗斯联邦, Kashirskoe shosse, 23, Moscow, 115522Oleg Yanushevich
A.I. Evdokimov Moscow State University of Medicine and Dentistry
Email: rectorat.mgmsu@gmail.com
ORCID iD: 0000-0003-0059-4980
Academician of RAS, Doctor of Medical Sciences, Professor, Rector
俄罗斯联邦, St. Delegatskaya, 20/2, Moscow, 127473Irina Boulytcheva
N.N. Blokhin National Medical Research Center of Oncology
Email: irena@boulytcheva.com
ORCID iD: 0000-0001-7592-4249
Doctor of Medical Sciences, Pathologist, Department of Morphological and Molecular Genetic Tumor Diagnostics
俄罗斯联邦, Kashirskoe shosse, 23, Moscow, 115522Ivan Stilidi
N.N. Blokhin National Medical Research Center of Oncology
Email: crcspine@rambler.ru
ORCID iD: 0000-0003-3672-1742
Candidate of Medical Sciences, Head
俄罗斯联邦, Kashirskoe shosse, 23, Moscow, 115522Nikolay Kushlinskii
N.N. Blokhin National Medical Research Center of Oncology; A.I. Evdokimov Moscow State University of Medicine and Dentistry
Email: kne3108@gmail.com
ORCID iD: 0000-0002-3898-4127
Academician of RAS, Doctor of Medical Sciences, Professor, Head of the Laboratory of Clinical Biochemistry
俄罗斯联邦, Kashirskoe shosse, 23, Moscow, 115522; St. Delegatskaya, 20/2, Moscow, 127473参考
补充文件
